TOPLINE Rozanolixizumab, an antibody targeting the neonatal Fc receptor for immunoglobulin G (IgG), showed modest improvement in pain interference and fibromyalgia impact among patients with severe fibromyalgia but did not significantly reduce pain intensity or fatigue. The primary endpoint met the prespecified one-sided statistical threshold but not the standard two-sided significance level…
Read More
Is Rozanolixizumab Effective in Severe Fibromyalgia?
